Sequential therapeutic targeting of ovarian Cancer harboring dysfunctional BRCA1

Sequential therapeutic targeting of ovarian Cancer harboring dysfunctional BRCA1

Abstract Background Poly (ADP-ribose) polymerase inhibitors (PARPi) have become the first targeted therapies available in the treatment of patients with high-grade serous ovarian cancer (HGSOC). We recently described a significant reduction in PARP1 protein levels in vitro and in vivo in patients tr...

Full description

Bibliographic Details
Main Authors: Tahira Baloch, Vanessa M. López-Ozuna, Qiong Wang, Emad Matanis, Roy Kessous, Liron Kogan, Amber Yasmeen, Walter H. Gotlieb
Format: Article
Language:English
Published: BMC 2019-01-01
Series:BMC Cancer
Subjects:
Ovarian Cancer
BRCA1/2
PARP inhibitor
Chemoresistance
DNA repair pathway
Synthetic lethality
Online Access:http://link.springer.com/article/10.1186/s12885-018-5250-4

Internet

http://link.springer.com/article/10.1186/s12885-018-5250-4

Similar Items